Michel Dahan - 27 Feb 2023 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, Chief Operating Officer
Signature
/s/ Carolyn Rucci, attorney-in-fact for Michel Dahan
Issuer symbol
AKBA
Transactions as of
27 Feb 2023
Net transactions value
-$8,205
Form type
4
Filing time
01 Mar 2023, 15:06:17 UTC
Previous filing
02 Mar 2022
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Sale $8,205 -10,090 -3.4% $0.8132 289,927 27 Feb 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
F2 Includes 1,500 shares of the Issuers common stock purchased on June 30, 2022, and 1,500 shares of the Issuers common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan.